Literature DB >> 30570863

Expression levels of TUBB3, ERCC1 and P-gp in ovarian cancer tissues and adjacent normal tissues and their clinical significance.

Yingjie Jia1, Shulan Sun, Xiang Gao, Xiaomin Cui.   

Abstract

PURPOSE: To investigate the expressions of class III β-tubulin (TUBB3), nucleotide excision repair cross-complementary gene 1 (ERCC1) and P-glycoprotein (P-gp) in ovarian cancer tissues and adjacent normal tissues and their clinical significance.
METHODS: Ovarian cancer patients undergoing surgical resection at the Department of Oncology of the Affiliated Hospital of Shandong Medical College from March 2012 to May 2016 were enrolled in this study, from which 166 cases of pathologically confirmed cancer tissues and 50 cases of adjacent normal tissues were collected. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the messenger RNA (mRNA) expression levels of TUBB3, ERCC1 and P-gp in ovarian cancer tissues and adjacent normal tissues, and their relationships with ovarian cancer clinical stage and grade of pathological differentiation were analyzed.
RESULTS: The expression levels of TUBB3, ERCC1 and P-gp in ovarian cancer tissues were significantly higher than those in adjacent normal tissues (p<0.05). The later the clinical stage of ovarian cancer was, the higher the expression levels of TUBB3, ERCC1 and P-gp were (p<0.05). The lower the pathological differentiation grade of ovarian cancer was, the higher the expression levels of TUBB3, ERCC1 and P-gp were (p<0.05). TUBB3, ERCC1 and P-gb were positively correlated with clinical stage and pathological differentiation grade.
CONCLUSION: TUBB3, ERCC1 and P-gp are involved in the occurrence and development of ovarian cancer and can be used as important indexes judging the severity of ovarian cancer, providing a reference for the occurrence and development of the disease in ovarian cancer patients in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30570863

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  5 in total

Review 1.  Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.

Authors:  Lu Huang; Zhi Liao; Zhixi Liu; Yan Chen; Tingwenli Huang; Hongtao Xiao
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

2.  Preliminary Evidence for a Hormetic Effect on DNA Nucleotide Excision Repair in Veterans with Gulf War Illness.

Authors:  Jean J Latimer; Abdullah Alhamed; Stefanie Sveiven; Ali Almutairy; Nancy G Klimas; Maria Abreu; Kimberly Sullivan; Stephen G Grant
Journal:  Mil Med       Date:  2020-02-13       Impact factor: 1.437

3.  The Influence of Interaction between Cadmium with 17β-Estradiol, 2-Methoxyestradiol and 16α-Hydroxyestrone on Viability and p-Glycoprotein in Ovarian Cancer Cell Line.

Authors:  Ewa Sawicka; Jolanta Saczko; Julita Kulbacka; Martyna Szydełko; Beata Szymańska; Agnieszka Piwowar
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

4.  Chemosensitizing effect and mechanism of imperatorin on the anti-tumor activity of doxorubicin in tumor cells and transplantation tumor model.

Authors:  Xin-Li Liang; Miao-Miao Ji; Zheng-Gen Liao; Guo-Wei Zhao; Xi-Lan Tang; Wei Dong
Journal:  Korean J Physiol Pharmacol       Date:  2022-05-01       Impact factor: 2.016

5.  The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma.

Authors:  Dan Li; Kaifeng Dong; Jing Su; Haitao Xue; Junhai Tian; Yongfeng Wu; Jingtian Wang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.